BIO campaign gathers pharma partners to lobby Congress against superbugs

  01 September 2019

Merck, Novo Holdings and several smaller drug developers are partnering with the Biotechnology Innovation Organization (BIO) trade group in a new initiative to spur research and development in the fight against superbugs.

The “Working to Fight AMR” awareness and lobbying campaign tackles the problem of drug development in antimicrobial-resistant drugs, as most big companies have already moved out of the low-margin business. Executives from Novo Holdings, Merck, Entasis Therapeutics, Evotec, Paratek Pharmaceuticals and Forge Therapeutics are lending expertise to the group, said Greg Frank, BIO’s director of infectious disease policy, who is heading up the coalition. He expects the companies to not only contribute ideas, but also provide real-world stories about what they’re doing and why they need help in the antimicrobial battle.

 
Further reading: Fierce Pharma
Author(s): Beth Snyder Bulik
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed